Get 10 Free Leads on us
Use our Chrome Extension & instantly connect with prospects
OBI Pharma
OBI Pharma, Inc., is a Taiwan biopharmaceutical company that was established in 2002. Its mission is to develop and license novel therapeutic agents for unmet medical needs against cancer targets such as Globo Series (including Globo H and SSEA-4), AKR1C3, Trop-2 and other promising targets. The company's novel first-in-class immuno-oncology portfolio against Globo H includes: Adagloxad Simolenin (formerly OBI-822) and OBI 833, a Globo H active immunotherapy vaccine; OBI-888 (Globo H mAb) and OBI-999 (Globo H ADC). The company's novel first-in-class AKR1C3 targeted therapy is OBI-3424 (small-molecule prodrug) that selectively releases a potent DNA alkylating agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme.
...Read MoreObi Pharma Inc
OBI Inc
Obi Pharma USA Inc
OBI Pharma
$9.7 M
106
2002
Here's a list of some of the top trending technologies and APIs used by OBI Pharma.
(4 Technologies)
(3 Technologies)
(2 Technologies)
(2 Technologies)
(1 Technologies)
Company | Employees | Revenue | Top technologies |
---|---|---|---|
Tanox | 151 | $10.7 M | |
Aligos Therapeutics | 68 | $13.8 M | |
PROTAGONIST THERAPEUTICS | 105 | $319.1 M | |
Dicerna | 300 | $192.8 M | |
Celldex Therapeutics | 160 | $8.3 M |